Feb 6 (Reuters) - Biocon Ltd BION.NS:
EQUILLIUM ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY EVALUATING ITOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
EQUILLIUM INC - ITOLIZUMAB GENERALLY WELL TOLERATED IN PHASE 2 STUDY
EQUILLIUM INC - ITOLIZUMAB ACHIEVES 16.7% ENDOSCOPIC REMISSION IN PHASE 2 STUDY
Source text: ID:nBwbcr7K5a
Further company coverage: BION.NS